A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Part of paid clinical trials in Montgomery, Alabama.
- Sponsor
- Novo Nordisk A/S
- Study ID
- NCT07639021
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- NNC0662-0419 — DRUGNNC0662-0419 will be administered subcutaneously.
- Semaglutide — DRUGSemaglutide will be administered subcutaneously.
- NNC0662-0419 Placebo — DRUGPlacebo matched to NNC0662-0419 will be administered subcutaneously.
- Semaglutide placebo — DRUGPlacebo matched to semaglutide will be administered subcutaneously.
Study Details
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
Key Dates
- Start date
- Jun 9, 2026
- Status verified
- Jun 2026
- Primary completion
- Jul 12, 2027
- Completion
- Jul 12, 2027
Study Design
- Enrollment
- 230 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: NNC0662-0419Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner.
- Placebo Comparator: NNC0662-0419 placeboParticipants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner.
- Experimental: SemaglutideParticipants will receive semaglutide administered subcutaneously in a dose-escalation manner.
- Placebo Comparator: Semaglutide placeboParticipants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner.
Primary Outcome Measure
Number of gastrointestinal adverse events [ Time Frame: From week 0 to week 39 ]
Central Contacts
- Novo Nordisk(+1) 866-867-7178
Locations (24)
Find similar trials in Montgomery, AL
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
- New Heart Imaging Techniques to Evaluate Possible Heart DiseaseRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland